In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GHTF's (Global Harmonisation Task Force) new-look website offers updates:

This article was originally published in Clinica

Executive Summary

The Global Harmonisation Task Force (GHTF) has revamped its website, incorporating details of the new Study Group 5 which is focusing on global regulatory convergence in the area of clinical evidence. The new item on SG5 confirms that Dr Graeme Harris, chief clinical adviser at the office of Device, Blood and Tissues at the Therapeutics Goods Administration of Australia, is chair of the study group and that it will meet in Canberra, Australia from January 17-19. Also featured on the updated website are summaries of the following meetings: the SG3 meeting in Erlangen, Germany, on September 14-16; the SG1 meeting in Lisbon on October 5-6; the SG4 meeting on September 27-29 in Canberra, Australia. In addition, there is a calendar of events for 2005 and a participants' list for SG4.

You may also be interested in...

Dosing Guidance Lacking For Leading COVID-19 Antiviral Therapies, ASHP Analysis Shows

Health-system pharmacist organization assesses the evidence behind off-label use of existing drugs for COVID-19, along with top investigational prospects like Gilead’s remdesivir. 

Quality Should Ride Shotgun As US Auto Makers Rev Engine On Making Ventilators

As American auto giants GM and Ford take the wheel on working with ventilator manufacturers to make the critically needed devices during the COVID-19 pandemic, two longtime quality experts explain where the device and auto companies will find common ground when it comes to quality systems.

PBMI: Managing Specialty Drug Costs, Working With ICER And Promoting Transparency

Despite a reprieve last summer from the Trump administration’s proposed drug price rebate rule, speakers at the 25th annual Pharmacy Benefit Manager Institute kept the focus on price transparency and talked up new ways to manage drug costs for patients in need of treatment. 





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts